Lucas Wong

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

Robert P. Whitehead, Cathryn Rankin, Paulo M. Hoff et al. · Investigational New Drugs · 2008 · 83 citations · Full text

Medicine, Oncology, Pharmacology +8

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

Cathy Eng, Joan Maurel, Werner Scheithauer et al. · Journal of Clinical Oncology · 2007 · 41 citations

Medicine, Oncology, Pharmacotherapy +16

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Hani M. Babiker, Vincent J. Picozzi, Sreenivasa R Chandana et al. · Journal of Clinical Oncology · 2025 · 38 citations · Full text

Medicine, Oncology, Pharmacology +9

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

Y. Abubakr, Cathy Eng, Lucas Wong et al. · Journal of Clinical Oncology · 2006 · 24 citations

Medicine, Oncology, Pharmacology +16